As of 2025-11-01, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 28.34 mil USD. CHRS's TTM EBITDA according to its financial statements is -126.89 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 17.2x | 15.1x |
| Forward P/E multiples | 14.4x - 18.5x | 15.2x |
| Fair Price | (13.78) - 2.71 | (6.28) |
| Upside | -920.3% - 61.4% | -474.0% |
| Date | EV/EBITDA |
| 2025-10-31 | -0.22 |
| 2025-10-30 | -0.24 |
| 2025-10-29 | -0.27 |
| 2025-10-28 | -0.28 |
| 2025-10-27 | -0.15 |
| 2025-10-24 | -0.20 |
| 2025-10-23 | -0.21 |
| 2025-10-22 | -0.22 |
| 2025-10-21 | -0.28 |
| 2025-10-20 | -0.32 |
| 2025-10-17 | -0.20 |
| 2025-10-16 | -0.25 |
| 2025-10-15 | -0.31 |
| 2025-10-14 | -0.24 |
| 2025-10-13 | -0.27 |
| 2025-10-10 | -0.21 |
| 2025-10-09 | -0.35 |
| 2025-10-08 | -0.30 |
| 2025-10-07 | -0.25 |
| 2025-10-06 | -0.24 |
| 2025-10-03 | -0.19 |
| 2025-10-02 | -0.21 |
| 2025-10-01 | -0.17 |
| 2025-09-30 | -0.19 |
| 2025-09-29 | -0.24 |
| 2025-09-26 | -0.06 |
| 2025-09-25 | -0.01 |
| 2025-09-24 | -0.13 |
| 2025-09-23 | -0.11 |
| 2025-09-22 | -0.14 |
| 2025-09-19 | -0.16 |
| 2025-09-18 | -0.09 |
| 2025-09-17 | 0.08 |
| 2025-09-16 | 0.07 |
| 2025-09-15 | 0.15 |
| 2025-09-12 | 0.13 |
| 2025-09-11 | 0.10 |
| 2025-09-10 | 0.12 |
| 2025-09-09 | 0.08 |
| 2025-09-08 | 0.06 |
| 2025-09-05 | 0.13 |
| 2025-09-04 | 0.12 |
| 2025-09-03 | 0.16 |
| 2025-09-02 | 0.23 |
| 2025-08-29 | 0.25 |
| 2025-08-28 | 0.23 |
| 2025-08-27 | 0.27 |
| 2025-08-26 | 0.28 |
| 2025-08-25 | 0.24 |
| 2025-08-22 | 0.19 |